Wnt family ligands

Miclxin (DS37262926) is a potent inhibitor of mutant β-catenin , involving in Wnt signaling pathway. Miclxin induces β-catenin-dependent apoptosis , leads to severe mitochondrial damage with the loss of mitochondrial membrane. Miclxin kills tumor

Miclxin (DS37262926) is a potent inhibitor of mutant β-catenin , involving in Wnt signaling pathway. Miclxin induces β-catenin-dependent apoptosis , leads to severe mitochondrial damage with the loss of mitochondrial membrane. Miclxin kills tumor

ML192 is a selective ligand antagonist of GPR55 . ML192 inhibits the β-arrestin trafficking, ERK1/2 phosphorylation and PKCβII translocationIn VitroML192 inhibits the β-arrestin trafficking induced by 10 μM L-α lysophosphatidylinositol (LPI) or 1 μM

ML192 is a selective ligand antagonist of GPR55 . ML192 inhibits the β-arrestin trafficking, ERK1/2 phosphorylation and PKCβII translocationIn VitroML192 inhibits the β-arrestin trafficking induced by 10 μM L-α lysophosphatidylinositol (LPI) or 1 μM

ML192 is a selective ligand antagonist of GPR55 . ML192 inhibits the β-arrestin trafficking, ERK1/2 phosphorylation and PKCβII translocationIn VitroML192 inhibits the β-arrestin trafficking induced by 10 μM L-α lysophosphatidylinositol (LPI) or 1 μM

ML192 is a selective ligand antagonist of GPR55 . ML192 inhibits the β-arrestin trafficking, ERK1/2 phosphorylation and PKCβII translocationIn VitroML192 inhibits the β-arrestin trafficking induced by 10 μM L-α lysophosphatidylinositol (LPI) or 1 μM

Mogrol is a biometabolite of mogrosides, and acts via inhibition of the ERK1/2 and STAT3 pathways, or reducing CREB activation and activating AMPK signaling.In VitroMogrol (0-250 µM) significantly and dose- and time-dependently inhibits K562 cell

Mogrol is a biometabolite of mogrosides, and acts via inhibition of the ERK1/2 and STAT3 pathways, or reducing CREB activation and activating AMPK signaling.In VitroMogrol (0-250 µM) significantly and dose- and time-dependently inhibits K562 cell

Mogrol is a biometabolite of mogrosides, and acts via inhibition of the ERK1/2 and STAT3 pathways, or reducing CREB activation and activating AMPK signaling.In VitroMogrol (0-250 µM) significantly and dose- and time-dependently inhibits K562 cell

Mogrol is a biometabolite of mogrosides, and acts via inhibition of the ERK1/2 and STAT3 pathways, or reducing CREB activation and activating AMPK signaling.In VitroMogrol (0-250 µM) significantly and dose- and time-dependently inhibits K562 cell

Mogrol is a biometabolite of mogrosides, and acts via inhibition of the ERK1/2 and STAT3 pathways, or reducing CREB activation and activating AMPK signaling.In VitroMogrol (0-250 µM) significantly and dose- and time-dependently inhibits K562 cell

Mogrol is a biometabolite of mogrosides, and acts via inhibition of the ERK1/2 and STAT3 pathways, or reducing CREB activation and activating AMPK signaling.In VitroMogrol (0-250 µM) significantly and dose- and time-dependently inhibits K562 cell